ProfileGDS5678 / 1424570_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 63% 66% 67% 67% 65% 67% 71% 64% 67% 68% 68% 66% 65% 66% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.7899963
GSM967853U87-EV human glioblastoma xenograft - Control 23.9500666
GSM967854U87-EV human glioblastoma xenograft - Control 34.0754167
GSM967855U87-EV human glioblastoma xenograft - Control 44.131867
GSM967856U87-EV human glioblastoma xenograft - Control 53.8710965
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.1128867
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.4275271
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.8041464
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.1118167
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.1225368
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.1260268
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.9597966
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.9114565
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.9578766